Clarient announced the launch of its new epidermal growth factor receptor mutation test to help physicians select the right treatment for non-small cell lung cancer patients.
The laboratory-developed test analyzes formalin-fixed, paraffin-embedded tissue samples and detects EGFR mutations to help determine which NSCLC patients will respond to tyrosine kinase inhibitor treatments. The RT-PCR assay detects "the most common mutations of the EGFR gene," according to the company.